Large gap with delayed quotes
|
Last quote
12/27/2024 -
17:20:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
27.99
-0.40
(
-1.41% )
|
27.99
|
100 |
28.00
|
100 |
Analysis date: 24.12.2024
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 20.12.2024.
Interest
Weak
Weak
Weak interest since 20.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 18.10.2024 at a price of 26.02.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Positive
Positive
The forty day Medium Term Technical Trend is positive since 26.11.2024. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 26.100.
4wk Rel Perf
4.05%
4.05%
The four week relative overperformance versus SP500 is 4.05%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 05.03.2024.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.20%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.94%.
Mkt Cap in $bn
5.25
5.25
With a market capitalization between $2 & $8bn, BRIDGEBIO PHARMA is considered a mid-cap stock.
G/PE Ratio
1.48
1.48
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
27.57
27.57
The estimated PE is for the year 2028.
LT Growth
40.70%
40.70%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
11
11
Over the last seven weeks, an average of 11 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
123
123
For 1% of index variation, the stock varies on average by 1.23%.
Correlation
0.30
0.30
Stock movements are strongly independent of index variations.
Value at Risk
14.45
14.45
The value at risk is estimated at USD 14.45. The risk is therefore 50.66%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
11.09.2020
11.09.2020